Last reviewed · How we verify

Rhgaa — Competitive Intelligence Brief

Rhgaa (ALGLUCOSIDASE ALFA) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]. Area: Metabolic.

marketed Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] Metabolic Enzyme Live · refreshed every 30 min

Target snapshot

Rhgaa (ALGLUCOSIDASE ALFA) — Sanofi. Rhgaa works by replacing the deficient enzyme in patients with Pompe disease.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rhgaa TARGET ALGLUCOSIDASE ALFA Sanofi marketed Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] 2006-01-01
Neogaa AVALGLUCOSIDASE ALFA Sanofi marketed Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] 2021-01-01
NEXVIAZYME AVALGLUCOSIDASE ALFA-NGPT GENZYME CORP marketed Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] class)

  1. Sanofi · 2 drugs in this class
  2. GENZYME CORP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rhgaa — Competitive Intelligence Brief. https://druglandscape.com/ci/alglucosidase-alfa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: